Company Overview - Medtronic is a leading global healthcare solutions company operating in the medical technology sector, developing and manufacturing medical devices and therapies for various health conditions [1] - The company competes with major players in the healthcare industry, including Johnson & Johnson and Boston Scientific [1] Stock Performance - Medtronic's stock is currently priced at $101, reflecting a slight increase of 0.21, or 0.21%, from the previous trading session [2] - The stock has fluctuated between a low of $99.69 and a high of $101.59 today, with a yearly high of $106.33 and a low of $79.55 [2] - The market capitalization of Medtronic is approximately $129.5 billion, with a trading volume of 7.67 million shares today [2] Analyst Coverage - CICC initiated coverage on Medtronic with a bullish view, assigning it an "Outperform" grade, indicating a positive outlook on the company's future [5] - The current stock price of $101 shows investor confidence, aligning with the positive outlook from CICC [5] Investment Strategy - Eaton Vance Worldwide Health Sciences Fund has reduced its stake in Novo Nordisk AS by 49.25%, indicating a strategic shift in its investment approach [3] - The fund targets companies involved in healthcare product and service innovation, driven by growth potential associated with aging demographics and increasing global incomes [3] - The fund's strategy emphasizes acquiring reasonably priced stocks with long-term growth potential, which aligns with the bullish view on Medtronic [4]

Core Insights - Thermo Fisher Scientific Inc. (TMO) reported fourth-quarter 2025 adjusted earnings per share (EPS) of $6.57, exceeding the Zacks Consensus Estimate by 2.1% and reflecting a year-over-year increase of 7.7% [1][9] - The company's full-year adjusted EPS reached $22.87, surpassing the Zacks Consensus Estimate by 0.6% and showing a 4.6% year-over-year growth [2] Revenue Performance - TMO's revenues for the fourth quarter increased by 7.1% year over year to $12.22 billion, exceeding the Zacks Consensus Estimate by 2.3% [3][9] - For the full year, revenues rose 3.9% year over year to $44.56 billion, also surpassing the Zacks Consensus Estimate by 0.6% [3] Segment Analysis - Life Sciences Solutions segment revenues (24.1% of total revenues) grew by 13.5% year over year to $2.95 billion [4] - Analytical Instruments segment revenues (18.1%) increased by 1.4% year over year to $2.22 billion [5] - Specialty Diagnostics segment revenues (10%) rose by 5.2% year over year to $1.22 billion [6] - Laboratory Products and Biopharma Services segment revenues (52.2%) increased by 7.4% year over year to $6.38 billion [7] Margin and Cost Analysis - The gross margin for the fourth quarter was 41.5%, contracting by 150 basis points year over year due to a 10% rise in the cost of revenues [8] - Selling, general, and administrative expenses increased by 7.1% to $1.98 billion, while research and development expenses decreased by 4.5% year over year to $357 million [8] Financial Position - At the end of the fourth quarter, TMO had cash and cash equivalents and short-term investments totaling $10.11 billion, a significant increase from $3.55 billion at the end of the third quarter [10] - Cumulative net cash from operating activities at the end of the fourth quarter was $7.82 billion, down from $8.67 billion a year ago [10] Strategic Developments - TMO made several high-impact product launches in the fourth quarter, including the Helios MX1 Plasma Focused Ion Beam Scanning Electron Microscope, and received FDA approval for the Ion Torrent Oncomine Dx Target Test and the EXENT System, which are expected to support future growth [12][13]

Core Insights - Boston Scientific (BSX) is expected to report its fourth-quarter 2025 results on February 4, with earnings per share (EPS) anticipated at 78 cents, reflecting an 11.4% growth year-over-year, and revenues projected at $5.27 billion, indicating a 15.4% increase from the previous year [1][2]. Group 1: Financial Performance - The Zacks Consensus Estimate for BSX's revenues is set at $5.27 billion, which represents a 15.4% increase compared to the same quarter last year [2]. - The consensus for earnings is pegged at 78 cents per share, indicating an 11.4% growth from the year-ago quarter [2]. - BSX has consistently beaten earnings estimates in the past four quarters, with an average surprise of 7.36% [1]. Group 2: Business Segment Performance - The MedSurg division is expected to maintain strong sales momentum, with revenues estimated at $1.80 billion, suggesting an 11.4% year-over-year increase, driven by the Endoscopy and Urology businesses [4][7]. - The Cardiovascular segment is projected to see a 17.5% increase in revenues to $3.46 billion, supported by the uptake of WATCHMAN and FARAPULSE products [9][14]. - The Neuromodulation segment is anticipated to grow, bolstered by the Pain franchise and the acquisition of Nalu Medical, which expands BSX's portfolio in peripheral nerve pain [6]. Group 3: Market Developments - The Endoscopy business within MedSurg is benefiting from the Axios platform and the adoption of innovative technologies like OverStitch and Mantis clip [4]. - The Cardiovascular business is expected to perform well due to strong growth in coronary therapies, particularly from the AGENT Drug-Coated Balloon and the WATCHMAN FLX Pro device's launch in China [10][11]. - The Peripheral Interventions unit is likely to continue its growth trend, despite challenges in the Chinese market, with strong performance in Interventional Oncology & Embolization [13].

This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Medical device mergers and acquisitions accelerated in the second half of 2025, propelled by several large deal announcements, according to a report released this month by Bain & Company. Medtech M&A brought in a total value of about $80 billion through Nov. 30, 2025, surpassing the previous three years. Much of the activity took place in the second half of the ye ...

Group 1: Gaming Industry Insights - Goldman Sachs anticipates another challenging quarter for Las Vegas, maintaining Las Vegas Sands as their top pick with a price target of $80, while lowering Wynn's target from $148 to $140, but still reiterating a buy rating for Wynn [1][2] - The decline in Las Vegas's performance is attributed to difficult comparisons post-pandemic, raising questions about whether the downturn is cyclical or secular [2] - Wynn's potential is linked to its Macau exposure and the upcoming Dubai Resort, expected to open within a year, which could significantly boost earnings [3] Group 2: Company Performance and Ratings - Cummins has been downgraded to "peer perform" from "outperform" due to a valuation downgrade despite expected strong earnings growth over the next two years [5] - The industrial sector, including Cummins, is noted for strong performance, with a focus on power generation business contributing to its momentum [6] - Boston Scientific has been underperforming recently, along with other medical device companies, indicating pressure in the sector [7] Group 3: Consumer Staples Sector - Morgan Stanley has reiterated an overweight rating for Monster Beverage, raising its target from $87 to $296, highlighting a positive outlook for consumer staples [9] - The consumer staples sector is viewed favorably, with Monster, Walmart, and Costco identified as key names that could drive growth in 2026 [10]

Group 1: Company Overview - Boston Scientific specializes in less invasive medical devices that are inserted into the human body through small openings or cuts, with products used in various medical fields including angioplasty, blood clot filtration, and cardiac rhythm management [7] - Approximately 36% of Boston Scientific's total sales come from foreign markets, indicating a significant international presence [7] Group 2: Market Analysis - The current trading volume for Boston Scientific stands at 6,852,637, with the stock price at $92.28, reflecting a neutral RSI indicator status [10] - A consensus target price of $100.0 has been established by market experts, with an analyst from Oppenheimer maintaining an Outperform rating on the stock [9] Group 3: Options Trading Insights - Recent analysis of options trading revealed 21 unusual trades for Boston Scientific, with 47% of traders showing bullish sentiment and 47% bearish [1] - The major market movers are focusing on a price range between $80.0 and $97.0 for Boston Scientific over the last three months [2] - A detailed snapshot of options activity indicates a mix of bullish and bearish trades, with notable call and put options reflecting varying investor sentiments [6]

Core Viewpoint - The fourth quarter of 2025 experienced a sharp 5% sell-off followed by a quick recovery, with global stocks reaching all-time highs, influenced by concerns over a potential AI bubble and subsequent strong earnings from NVIDIA [4][5]. Portfolio Performance & Attribution - The Polen Global Growth Composite Portfolio returned -2.5% gross of fees and -2.7% net of fees in Q4 2025, underperforming the MSCI All Country World Index, which returned +3.3% [7]. - Top relative contributors included Eli Lilly, Alphabet, and Shopify, while Oracle, Paycom Software, and CoStar Group were the largest detractors [7][8]. - Eli Lilly's stock rallied over 40% in Q4 due to strong financial results and a favorable agreement on drug pricing, despite earlier concerns [8]. - Oracle's performance reversed from the previous quarter, primarily due to skepticism regarding its future revenue tied to OpenAI, impacting its stock negatively [9]. Portfolio Activity - New positions were initiated in Tencent Holdings and Spotify, while positions in Sage Group, Willis Towers Watson, ICON Plc, and Workday were eliminated to fund these investments [10][11]. - Tencent has shown consistent earnings growth of over 30% annually for the past three years, and its valuation is considered reasonable for sustainable revenue growth [11]. - Spotify is viewed as a leading streaming network with significant growth potential, expecting over 20% annual free cash flow growth for the next five years [12]. Outlook - The datacenter capital expenditure cycle is expected to continue, driven by increasing demand and supportive government policies, suggesting a favorable environment for growth in revenues and earnings for key players [17]. - The portfolio is positioned to deliver above-average earnings growth, with a focus on sectors outside of the AI and datacenter themes, ensuring resilience regardless of market drivers [18].

Core Viewpoint - Boston Scientific (BSX) has experienced a downtrend with a 6.3% decline over the past four weeks, but it is now in oversold territory, suggesting a potential turnaround due to analysts' positive earnings outlook [1]. Group 1: Technical Indicators - The Relative Strength Index (RSI) is a momentum oscillator that indicates whether a stock is oversold, with readings below 30 typically signaling this condition [2]. - BSX's current RSI reading is 29.38, indicating that heavy selling may be exhausting itself, which could lead to a price rebound [5]. - RSI helps identify potential reversal points, allowing investors to seek entry opportunities when a stock is undervalued due to excessive selling pressure [3]. Group 2: Fundamental Indicators - There is a strong consensus among sell-side analysts regarding BSX, with a 0.1% increase in the consensus EPS estimate over the last 30 days, suggesting a positive trend in earnings estimates [7]. - An upward trend in earnings estimate revisions is typically associated with price appreciation in the near term [7]. - BSX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks, indicating a strong potential for a turnaround [8].

Company Overview - Boston Scientific (BSX) is a $133 billion company with $19 billion in revenue, currently trading at $90.03 [2] - The company has achieved a revenue growth of 21.6% over the last 12 months and has an operating margin of 19.2% [2] Recent Stock Performance - BSX shares have decreased by 8.5% over the past 5 trading days, raising concerns about the impact of the Penumbra acquisition on earnings [2] - The stock has a P/E multiple of 47.8 and a P/EBIT multiple of 37.0, indicating a very high valuation [5] Historical Resilience - BSX stock has shown varying resilience during past economic downturns, performing slightly worse than the S&P 500 index [4] - The stock experienced a peak-to-trough decline of 25.2% during the 2022 inflation shock, but fully regained its pre-crisis peak by December 2022 [6] - During the 2020 COVID pandemic, BSX stock fell 43.5% but recovered to its pre-crisis peak by August 2021 [6] - In the 2018 correction, the stock decreased by 18.7% but also fully recovered by February 2019 [7] - The stock faced a significant decline of 70.5% during the 2008 financial crisis but regained its peak by November 2015 [7]

Group 1 - Boston Scientific (BSX) is actively pursuing its M&A strategy while also achieving impressive organic growth, with nearly 20% organic sales growth reported [1] - The company's shares are currently commanding premium earnings valuations, indicating strong market confidence [1] - The investment group "Value In Corporate Events" focuses on identifying opportunities in major corporate events such as IPOs, mergers & acquisitions, and earnings reports, providing coverage of 10 major events monthly [1]